|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stadel BV: Letter: The etiology and
prevention of ovarian cancer. Am J Obstet Gynecol. 123:772–774.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mertens-Walker I, Baxter RC and Marsh DJ:
Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett.
324:152–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Venn A, Watson L, Bruinsma F, Giles G and
Healy D: Risk of cancer after use of fertility drugs with in-vitro
fertilisation. Lancet. 354:1586–1590. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brekelmans CT: Risk factors and risk
reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol.
15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tavani A, Ricci E, La Vecchia C, Surace M,
Benzi G, Parazzini F and Franceschi S: Influence of menstrual and
reproductive factors on ovarian cancer risk in women with and
without family history of breast or ovarian cancer. Int J
Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daly M and Obrams GI: Epidemiology and
risk assessment for ovarian cancer. Semin Oncol. 25:255–264.
1998.PubMed/NCBI
|
|
9
|
Gnagy S, Ming EE, Devesa SS, Hartge P and
Whittemore AS: Declining ovarian cancer rates in U.S. women in
relation to parity and oral contraceptive use. Epidemiology.
11:102–105. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng W, Lu JJ, Luo F, Zheng Y, Feng Yj,
Felix JC, Lauchlan SC and Pike MC: Ovarian epithelial tumor growth
promotion by follicle-stimulating hormone and inhibition of the
effect by luteinizing hormone. Gynecol Oncol. 76:80–88. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurbacher CM, Jäger W, Kurbacher JA, Bittl
A, Wildt L and Lang N: Influence of human luteinizing hormone on
cell growth and CA 125 secretion of primary epithelial ovarian
carcinomas in vitro. Tumour Biol. 16:374–384. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuroda H, Mandai M, Konishi I, Yura Y,
Tsuruta Y, Hamid AA, Nanbu K, Matsushita K and Mori T: Human
chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis
in ovarian cancer cells: Possible role of up-regulation of
insulin-like growth factor-1 by hCG. Int J Cancer. 76:571–578.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tashiro H, Miyazaki K, Okamura H, Iwai A
and Fukumoto M: c-myc over-expression in human primary ovarian
tumours: Its relevance to tumour progression. Int J Cancer.
50:828–833. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tourgeman DE, Lu JJ, Boostanfar R, Amezcua
C, Felix JC and Paulson RJ: Human chorionic gonadotropin suppresses
ovarian epithelial neoplastic cell proliferation in vitro. Fertil
Steril. 78:1096–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi JH, Choi KC, Auersperg N and Leung
PC: Gonadotropins activate proteolysis and increase invasion
through protein kinase A and phosphatidylinositol 3-kinase pathways
in human epithelial ovarian cancer cells. Cancer Res. 66:3912–3920.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tilly JL, Tilly KI, Kenton ML and Johnson
AL: Expression of members of the bcl-2 gene family in the immature
rat ovary: Equine chorionic gonadotropin-mediated inhibition of
granulosa cell apoptosis is associated with decreased bax and
constitutive bcl-2 and bcl-xlong messenger ribonucleic acid levels.
Endocrinology. 136:232–241. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia L, Wen H, Han X, Tang J and Huang Y:
Luteinizing hormone inhibits cisplatin-induced apoptosis in human
epithelial ovarian cancer cells. Oncol Lett. 11:1943–1947. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu C, Shahzad MM, Moreno-Smith M, Lin YG,
Jennings NB, Alle JK, Landen CN, Mangala LS, Armaiz-Pena GN,
Schmandt R, et al: Targeting pericytes with a PDGF-B aptamer in
human ovarian carcinoma models. Cancer Biol Ther. 9:176–182. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guide for the Care and Use of Laboratory
Animals, . National Research Council (US) Committee for the update
of the guide for the care and use of laboratory animals. 8th.
Washington (DC): National Academies Press (US); 2011
|
|
21
|
Huang Y, Jin H, Liu Y, Zhou J, Ding J,
Cheng KW, Yu Y and Feng Y: FSH inhibits ovarian cancer cell
apoptosis by up-regulating survivin and down-regulating PDCD6 and
DR5. Endocr Relat Cancer. 18:13–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garofalo A, Naumova E, Manenti L, Ghilardi
C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E,
Nicoletti MI and Giavazzi R: The combination of the tyrosine kinase
receptor inhibitor SU6668 with paclitaxel affects ascites formation
and tumor spread in ovarian carcinoma xenografts growing
orthotopically. Clin Cancer Res. 9:3476–3485. 2003.PubMed/NCBI
|
|
23
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fisher DE: Apoptosis in cancer therapy:
Crossing the threshold. Cell. 78:539–542. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu
X, Yu Y, Zha X and Feng Y: Activation of the PI3K/AKT pathway
mediates FSH-stimulated VEGF expression in ovarian serous
cystadenocarcinoma. Cell Res. 18:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Liao H, Chen X, Zheng Y, Liu Y,
Tao X, Gu C, Dong L, Duan T, Yang Y, et al: Luteinizing hormone
upregulates survivin and inhibits apoptosis in ovarian epithelial
tumors. Eur J Obstet Gynecol Reprod Biol. 155:69–74. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xia L, Wen H, Han X, Tang J and Huang Y:
Luteinizing hormone inhibits cisplatin-induced apoptosis in human
epithelial ovarian cancer cells. Oncol Lett. 11:1943–1947. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liao H, Zhou Q, Gu Y, Duan T and Feng Y:
Luteinizing hormone facilitates angiogenesis in ovarian epithelial
tumor cells and metformin inhibits the effect through the mTOR
signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI
|
|
29
|
Rzepka-Górska I, Chudecka-Głaz A and
Kosmowska B: FSH and LH serum/tumor fluid ratios and malignant
tumors of the ovary. Endocr Relat Cancer. 11:315–321. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY
and Kim SH: Melatonin synergistically enhances cisplatin-induced
apoptosis via the dephosphorylation of ERK/p90 ribosomal S6
kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res.
52:244–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mabuchi S, Altomare DA, Cheung M, Zhang L,
Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR:
RAD001 inhibits human ovarian cancer cell proliferation, enhances
cisplatin-induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tan O and Bukulmez O: Biochemistry,
molecular biology and cell biology of gonadotropin-releasing
hormone antagonists. Curr Opin Obstet Gynecol. 23:238–244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
